Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Monitoring disease progression among HIV-infected adults using the immune activation assay suPARnostic at the Mater Hospital, Nairobi Kenya

Project: Types of projectsProject

  • Eugen-Olsen, Jesper (Project Manager, academic)
  • Marnane, Sr. Brigid , Kenya (Project Manager, organisational)
  • Mwachari, Dr. C. , Kenya (Project participant)
  • Vaughan, Mr. J. , Kenya (Project participant)
  • Pahe, Dr. C. , Kenya (Project participant)
  • Kanyingi, Ms. J. , Kenya (Project participant)
  • Krogsgaard, Lars , ViroGates, Denmark, Denmark (Project Manager, academic)
  • Andersen, Tine , ViroGates, Denmark , Denmark (Project Coordinator)
View graph of relations
The aim of the current study is to gain insight into the clinical and prognostic value of the plasma suPAR protein biomarker. Several studies in African and European countries have shown that suPAR is a strong prognostic biomarker for the disease progression of HIV infected patients. The prognostic value is similar to, or stronger than, the CD4 count and the HIV viral load. However, none of the studies have addressed the value of the suPAR biomarker in a randomised intervention study. We aim to include 510 HIV positive patients and follow them for 6 months after enrolment. SuPAR levels will be measured in plasma from samples already obtained for CD4 enumeration. Our hypothesis is that a low suPAR is associated with good prognosis while a high suPAR level is associated with continued risk of HIV disease progression. If the hypothesis is confirmed in the present study, we aim to conduct a randomised intervention study testing the clinical value of suPAR in disease management.

Prospects of a second study if hypothesis in the current study are confirmed. The second study is a randomised controlled study that could enlighten the following hypothesis:
• Naïve HIV patients with CD4 count above 500 and suPAR below 3.5 ng/ml can wait 12 months until next clinical/laboratory investigation.
• Patients with low immune activation (low suPAR) can wait 12 months until next clinical/laboratory investigation.
• High suPAR is associated with lipodystrophia. A forthcoming problem in Africa.
• A randomised study as outlined below
StatusCompleted
Period14/08/2014 → …

ID: 44480416